RBC cuts Jazz Pharmaceuticals price target to $296
Benzinga reports RBC Capital cut its Jazz Pharmaceuticals price target to $296 per share from $299.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.